Utter Christine Marie's Form 4 filing
PTC Therapeutics, Inc. (PTCT) · filed Dec 4, 2024
- Accession no.
- 0001415889-24-028286
- Filed
- Dec 4, 2024
- Trade date
- Dec 2, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $921.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Utter Christine MarieCIK 0001707685 | Officer (SVP, CHIEF ACCOUNTING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Common Stock | MOption exerciseAcquired | +3,105 | $51.00 | +$158,355 | 55,533 | Direct | |
| Dec 2, 2024 | Common Stock | SSaleDisposed | −2,497 | $51.34F2 | −$128,195.98 | 53,036 | Direct | |
| Dec 2, 2024 | Common Stock | SSaleDisposed | −608 | $52.24F3 | −$31,761.92 | 52,428 | Direct | |
| Dec 2, 2024 | Common Stock | MOption exerciseAcquired | +14,695 | $51.00 | +$749,445 | 67,123 | Direct | |
| Dec 2, 2024 | Common Stock | SSaleDisposed | −9,919 | $51.53F4 | −$511,126.07 | 57,204 | Direct | |
| Dec 2, 2024 | Common Stock | SSaleDisposed | −4,776 | $52.45F5 | −$250,501.2 | 52,428 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Common Stock | MOption exerciseDisposed | −3,105 | $0.00 | $0 | 14,695 | Direct | |
| Dec 2, 2024 | Common Stock | MOption exerciseDisposed | −14,695 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.15 to $52.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.16 to $52.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.15 to $52.11 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.15 to $52.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.